- Open Access
- Open Peer Review
Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines
Population Health Metricsvolume 12, Article number: 12 (2014)
Screening to detect prediabetes and diabetes enables early prevention and intervention. This study describes the number and characteristics of asymptomatic, undiagnosed adults in the United States who could be detected with prediabetes and type 2 diabetes using the American Diabetes Association (ADA) guidelines compared to the United States Preventive Services Task Force (USPSTF) guidelines.
We developed predictive models for undiagnosed diabetes and prediabetes using polytomous logistic regression from data on risk factors in the 2003–2010 National Health and Nutrition Examination Survey (n = 19,056). We applied these predictive models to the 2010 Medical Expenditure Panel Survey, which contains health care use data, to generate probabilities of undiagnosed diabetes and undetected prediabetes for each adult. We summed individual probabilities to estimate the number of adults who would be detected with prediabetes and/or type 2 diabetes if screened under ADA or USPSTF guidelines. We analyzed health care use patterns of people at high risk for diabetes.
In 2010, 59.1 million adults met the USPSTF screening criteria including 24.4 million people with undetected prediabetes and 3.7 million people with undiagnosed diabetes. In comparison, among the 86.3 million people who met the ADA screening criteria, there were 33.9 million with undetected prediabetes and 4.6 million with undiagnosed type 2 diabetes. The ADA guidelines detected 38.9% more cases of prediabetes and 24.3% more cases of type 2 diabetes compared to the USPSTF guidelines. Subgroup analysis showed that ADA guidelines would detect 78% more cases of diabetes among the age 54 and younger population, in 40% more blacks, and in more than twice as many Hispanics than USPSTF guidelines. Only 58% of adults meeting ADA guidelines and 70% meeting USPSTF guidelines had ≥ 1 primary care office visit in 2010.
Compared to USPSTF guidelines, ADA guidelines would screen more people and detect more cases of both prediabetes and type 2 diabetes, though a substantial percentage of patients with undetected cases had no contact with a primary care provider in 2010. Addressing the problem of large numbers of undetected prediabetes and type 2 diabetes cases will require new strategies for screening.
Type 2 diabetes is a large, costly, and growing epidemic in the US . Evidence-based interventions are available to prevent or delay the onset of diabetes in people with prediabetes [2, 3] and to reduce rates of complications among those with type 2 diabetes . More than one-fourth of the estimated 26 million Americans with diabetes remain undiagnosed, and more than 90% of the estimated 79 million adults with prediabetes remain undetected . As with many diseases, screening and early detection of diabetes and prediabetes is the first step to initiating prevention and treatment interventions, and have received considerable interest [6–8]. Screening is recommended within a health care setting, usually by a primary care provider, so that appropriate follow-up testing and care can be delivered .
US and international organizations have recommended various guidelines for screening for type 2 diabetes in asymptomatic adults, but these guidelines differ in the number and types of risk factors they target [4, 8–12]. The United States Preventive Services Task Force (USPSTF), an independent panel of experts that conducts scientific reviews of preventive health care services, recommends screening only adults with sustained hypertension (either treated or untreated) greater than 135/80 mm Hg . In comparison, the American Diabetes Association (ADA) recommends broader screening criteria by targeting everyone age 45 and older as well as overweight adults of any age who have additional risk factors, including family history of diabetes, being a member of a high-risk racial/ethnic population, physical inactivity, high cholesterol, signs of insulin resistance (such as acanthosis nigricans), polycystic ovarian syndrome, history of gestational diabetes, or previous diagnosis of prediabetes, as well as having hypertension . For adults age 45 and older with normal test results, the ADA recommends repeat testing at least every three years. Other organizations have also endorsed guidelines that encompass multiple risk factors to screen for asymptomatic adults—including the American Heart Association, the American College of Physicians, The Endocrine Society, and the Veterans Health Administration [13–16]. While USPSTF guidelines are designed to detect diabetes, ADA guidelines are designed to detect both diabetes and prediabetes.
The number of people screened and detected with diabetes or prediabetes in a given population will differ depending on which guidelines are followed. For example, analysis of an ambulatory population seen at one large physician practice found following the ADA guidelines would detect 50% more cases of undiagnosed diabetes than would be detected if following the USPSTF guidelines . A study modeling simulated screening strategies found that screening based on USPSTF guidelines identified fewer people with diabetes compared to screening initiated at age 45, as recommended by the ADA .
Our study investigates two sets of questions with respect to USPSTF and ADA screening guidelines: (1) How many people in the US in 2010 could have been screened and identified with diabetes and prediabetes under each set of guidelines, and what are the characteristics of populations detected with prediabetes and diabetes? (2) What are the health care use patterns of adults at high risk for prediabetes or diabetes, and how does this affect the ability to implement USPSTF and ADA guidelines?
We used the 2003–2010 waves of the National Health and Nutrition Examination Survey (NHANES), a major nationally representative survey of the US non-institutionalized population, to develop predictive models for undiagnosed diabetes and undetected diabetes . NHANES includes detailed health information and characteristics, including whether a respondent has ever been told by a health care professional that he or she has diabetes or prediabetes. A random sample of approximately one-third of NHANES adults receives laboratory tests to provide more detailed descriptions of their health status. Comparison of self-reported glycemic status with laboratory tests provides an opportunity to develop a clinically based model of undiagnosed glycemic disease. These laboratory tests include hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and/or oral glucose tolerance test (OGTT). Many individuals receive more than one test type.
We used the 2010 Medical Expenditure Panel Survey (MEPS) to analyze health care use patterns and estimate the number of people whose diabetes or prediabetes could be detected using the ADA and USPSTF screening guidelines . Like NHANES, MEPS collects detailed information on patient characteristics, health-related behavior, and presence of chronic conditions. MEPS does not contain lab values but does collect detailed information on health care use patterns for each participant over a one-year period. MEPS contains a self-reported indication of previous diabetes diagnosis, but includes no data on previous prediabetes diagnosis. Both surveys contain sample weights to generalize from the sample to the US population, and weights were used in the regression analyses and to generate summary statistics.
Selection and exclusion criteria
Exclusion criteria for our analysis included women who indicated they were pregnant at the time of their NHANES lab test (n = 425), as well as people who indicated that they had previously been told by a health care professional that they have diabetes or for whom there was an indication of treatment for diabetes (n = 2,300). This provides a sample of 19,056 individuals with lab results— including 9,855 who received only the HbA1c test; 5,809 who received all three tests (HbA1c, FPG, and OGTT); 3,362 who received both HbA1c and FPG; 18 who received FPG and OGTT; seven who received only FPG; and five who received both HbA1c and OGTT. We applied similar exclusion criteria for the MEPS analysis, restricting the population to non-pregnant adults age 18 and older without diagnosed diabetes (n = 21,774).
Definitions of key variables
Using lab values in NHANES, diabetes was defined as OGTT ≥ 200 at two hours or FPG ≥ 126 or HbA1c ≥ 6.5; prediabetes was defined as 199 ≥ OGTT ≥ 140 at two hours, 125 ≥ FPG ≥ 100, or 6.4 ≥ HbA1c ≥ 5.7 . We categorized people as having diabetes if any of their lab tests were in the diabetes range. For individuals not categorized as having diabetes, we categorized them as having prediabetes if any of their test results were in the prediabetes range. A limitation of NHANES, discussed later, is that no follow-up confirmatory test is available, and research suggests that using a single test can result in false positives or negatives .
For modeling purposes, we placed each NHANES adult into one of four categories: undiagnosed diabetes, diagnosed prediabetes, undetected prediabetes, or normal lab levels. Undiagnosed diabetes and undetected prediabetes were defined by a negative response to the question “have you ever been told by a health care professional that you have diabetes or prediabetes?” and a positive finding for diabetes or prediabetes on the lab test results .
We selected explanatory variables for the regression analysis (described later) based on established [9, 10, 23–27] risk factors for diabetes that are common to the NHANES and MEPS databases, as well as variables associated with greater access to or use of health care services. All variables were coded as dichotomous indicators (characteristic applies = 1, else = 0), with the exception of family income (measured continuously in thousands of 2010 dollars). Variables used were sex; six age groups (18–34, 35–44, 45–54, 55–64, 65–74, and 75+ years); race/ethnicity (non-Hispanic white, non-Hispanic black, non-Hispanic other, and Hispanic); previous diagnoses or history of asthma, arthritis, heart attack, stroke, cancer, hypertension, high cholesterol, and cardiovascular disease; current smoker; body weight defined by body mass index —normal (BMI < 25), overweight (25 ≤ BMI < 30), or obese (30 ≤ BMI); has medical insurance; is insured through Medicaid; and survey year. While arthritis and asthma are not recognized risk factors for diabetes, we included these indicators because patients with these conditions have more annual visits with health care providers, which could increase the number of opportunities for screening. Including these two conditions might also result in earlier identification of diabetes or prediabetes if such patients were treated with corticosteroids, in light of the known hyperglycemic effect of these medications. Our analysis omitted ADA screening risk factors for which data are unavailable in NHANES or MEPS (family history of diabetes, polycystic ovarian syndrome, or gestational diabetes).
Statistical analysis plan
Using NHANES data for those individuals not previously diagnosed with diabetes (n = 19,056), we estimated a polytomous logistic predictive model. This regression approach allowed us to model a dependent variable with three values: normal glucose levels, prediabetes (both diagnosed and undiagnosed), and undiagnosed diabetes, and thus provided estimated risks for both diabetes and prediabetes . We applied this predictive model from NHANES to each adult in MEPS to generate individual probabilities of undiagnosed diabetes and prediabetes based on each person’s demographic, health, and socioeconomic characteristics.
Separate from the polytomous logistic regression, we used logistic regression to quantify the relationship between patient characteristics and diagnosed prediabetes (n = 676). We used the same explanatory variables as described previously, with the dependent variable indicating previous detection of prediabetes. We applied this second regression to the MEPS sample to estimate each person’s probability of previous prediabetes detection. The total probability of prediabetes minus the probability of detected prediabetes provided an estimated probability of undetected prediabetes for each person.
We then identified adults in the MEPS who would be screened under the USPSTF and ADA screening guidelines and summed their predicted probabilities for undetected prediabetes and undiagnosed diabetes to provide estimates of the potential number of people in the US who could be detected under each screening guideline. Consider, for example, an individual with a predicted probability of 0.3 for undetected prediabetes and 0.1 for undiagnosed diabetes, and with a sample weight of 1000 (meaning this person represents 1,000 people in the US population). If this sample person met the screening criteria, then he or she represents 1,000 people screened, 300 people (0.3 × 1,000) in whom prediabetes would be detected, and 100 people (0.1 × 1,000) in whom diabetes would be diagnosed.
When modeling the ADA screening guidelines (using those risk factors available in MEPS), if a person met the criteria only because he or she was over age 45 (that is, was not overweight or had no other risk factors), we modeled this person as having a one-in-three probability of being screened during the year. This assumption was to simulate the ADA recommendation that a person over age 45 with no risk factors should be re-screened every three years.
We then used MEPS to analyze health care use patterns of people who met the ADA and USPSTF screening criteria to estimate the number of detection (screening) opportunities that exist under current patterns of usage.
To validate the predictive modeling approach, we randomly divided the NHANES sample into two groups with 9,528 observations each. We estimated a predictive model for prediabetes and undiagnosed diabetes with one group, and then applied the model to the second group. For the second group, we compared the sum of predicted probabilities of prediabetes and undiagnosed diabetes with the clinical indication of prediabetes or undiagnosed diabetes. The analysis suggests that the predictive modeling approach reliably estimated total cases of prediabetes and undiagnosed diabetes in the population by age group. Regressions estimated with both subsets of NHANES produced similar coefficients, so we used the full NHANES sample to generate the results presented in this paper.
NHANES sample and predictive model
Summary statistics for the NHANES sample are consistent with the published literature and are summarized in Table 1. Approximately 90% of prediabetes cases were undetected. Characteristics associated with higher odds of having undiagnosed diabetes or prediabetes include male, older age, minority race and Hispanic, hypertension, hypercholesterolemia, cardiovascular disease, smoking, and excess body weight (Table 2) . Having medical insurance and higher annual family income are associated with lower odds of prediabetes and undiagnosed diabetes. Many of the factors associated with prediabetes and undiagnosed diabetes are the same as those associated with diagnosed diabetes. Variation across NHANES years could be due in part to changes in laboratory methodology across different NHANES years.
Applying the predictive model to MEPS adults who do not have diagnosed diabetes produced probabilities of undiagnosed diabetes ranging from 0.3% to 26.2%. Whereas the person among the MEPS sample with the lowest predicted probability of undiagnosed diabetes is a young, non-Hispanic white, high-income female with no history of chronic conditions and no known risk factors for diabetes, the person with the highest predicted probability is older, male, non-Hispanic other (non-black) minority, obese, and with a history of hypertension, high cholesterol, and cardiovascular disease.
Characteristics associated with statistically higher probability of undiagnosed diabetes (Figure 1) and prediabetes (Figure 2) include older age, excess body weight, racial or ethnic minority, male, hypertension, cardiovascular disease, dyslipidemia, and smoking. These characteristics substantially overlap risk factors in the ADA guidelines. Being obese (versus normal weight) is associated with a 4.8 percentage point increase in probability of undiagnosed diabetes among a population age 45 to 54 with population mean values for the other risk factors.
USPSTF vs. ADA guidelines: Diabetes and prediabetes cases detected
The US had approximately 7 million adults with undiagnosed diabetes and 79 million with undetected prediabetes in 2010 . Our analysis suggests that 59.1 million adults in the US meet the USPSTF screening guidelines, and screening of all these individuals would detect 3.7 million people with diabetes and 24.4 million with prediabetes—or about half (53%) the cases of undiagnosed diabetes and one-third (31%) of the cases of undetected prediabetes (Tables 3 and 4). Such findings are consistent with research suggesting that approximately half of the people with undiagnosed diabetes do not meet USPSTF screening guidelines . In contrast, 86.3 million adults meet ADA guidelines (assuming that one in three adults age 45 or older without other risk factors were screened in a given year), and screening these adults would detect 4.6 million people with diabetes and 33.9 million people with prediabetes.
ADA guidelines would detect nearly 1.5 million diabetes cases that would be missed under USPSTF guidelines (Table 3). USPSTF guidelines would detect 587,000 diabetes cases that would be missed under ADA guidelines in the initial year of fully implementing the latter guidelines, but these include adults over age 45 who would be screened in subsequent years. Under the ADA guidelines, within three years all adults age 45 and older would be screened.
ADA guidelines identify substantially more individuals in minority populations as having diabetes and prediabetes than do USPSTF screening guidelines. ADA guidelines detect 40% more blacks and more than twice as many Hispanics with diabetes relative to USPSTF guidelines (Table 3). Nearly 80% more blacks and more than three times as many Hispanics would be detected with prediabetes using ADA guidelines compared to USPSTF guidelines (Table 4). Among Hispanics, USPSTF guidelines miss 5.4 million people with prediabetes who would be detected using ADA guidelines. In comparison, ADA guidelines would miss only 408,000 with prediabetes that would be detected using USPSTF guidelines.
USPSTF guidelines both screen and detect a significantly older population. Whereas 35% of people with diabetes detected under ADA guidelines are age 65 and older, 46% of people detected under USPSTF guidelines are age 65 or older.
Health care use patterns and risk for undiagnosed diabetes or prediabetes
The above MEPS analysis illustrates the number of people in the US who could be screened and for whom diabetes or prediabetes could be detected applying USPSTF and ADA guidelines population-wide. In general, though, screening occurs opportunistically when patients visit a health care provider during an office visit, outpatient or emergency visit, or when hospitalized. Therefore, we analyzed the health care use patterns for people at high risk for undiagnosed diabetes or prediabetes—in particular, patterns of visiting a primary care provider in 2010—to understand what segment of the population had the opportunity to be screened during that year.
Across the entire US population of adults without diagnosed diabetes and excluding pregnant women, our MEPS analysis suggests that 67% of visits within the health care system were office visits to specialist providers; 22% were visits to primary care providers; and the rest consisted of hospital outpatient visits (7%), emergency department visits (3%) and inpatient hospitalizations (1%).
Strikingly, we found that having a greater number of annual visits within the health care system is positively correlated with a higher probability of undiagnosed diabetes, suggesting that multiple opportunities for diabetes detection are being missed (Table 5). For example, adults having a less than 5% probability for undiagnosed diabetes averaged 4.7 visits in 2010; adults with 5%-10% probability averaged 8.8 visits; and adults with a greater than 10% probability of undiagnosed diabetes averaged 10.7 visits. Adults meeting the ADA screening criteria averaged 6.9 visits, while adults meeting the USPSTF screening criteria averaged 9.1 visits. For comparison, people with diagnosed diabetes averaged 11.7 visits. While averages can be sensitive to outliers, across all the care delivery settings modeled there is a clearly observed relationship between patient probability of undetected diabetes or prediabetes and increasing average annual visits.
Opportunities to detect diabetes during primary care office visits
We estimate that the US adult population without diagnosed diabetes made approximately 256 million visits to a primary care provider in 2010. In addition, 58% (50 million people) of adults meeting the ADA diabetes screening criteria had at least one primary care visit in 2010, and among these were an estimated 3.1 million patients with undiagnosed diabetes and 20.4 million with undetected prediabetes (Table 6). Of those adults meeting the USPSTF criteria, 70% (41.5 million people) had at least one primary care visit in 2010, and among these were 2.8 million cases of undiagnosed diabetes and 17.3 million cases of undetected prediabetes.
Of the estimated 4.6 million adults with undiagnosed diabetes meeting the ADA screening criteria, 66% could have been identified in 2010 if the criteria had been applied during visits to a primary care provider. Of the 3.7 million adults in the US who have undiagnosed diabetes and who meet the USPSTF screening criteria, 74% could have been identified in 2010 if those criteria had been applied during visits to a primary care provider. For comparison, the CDC estimates that 1.9 million people in the US are newly diagnosed with diabetes each year , suggesting that large numbers of asymptomatic adults who meet screening criteria are not being tested.
In this study, we compared two strategies to diagnose currently undiagnosed cases of prediabetes and type 2 diabetes. Our research aimed to answer two sets of questions: (1) How many people in the US in 2010 could have been screened and identified with diabetes and prediabetes under ADA and USPSTF guidelines, and what are the characteristics of populations detected with prediabetes and diabetes? (2) What are the health care use patterns of adults at high risk for prediabetes or diabetes, and how does this affect the ability of primary care providers to implement USPSTF and ADA guidelines? These findings have implications for identifying the most efficient screening strategies.
Comparison of ADA and USPSTF guidelines to address the first set of questions suggests three key implications:
ADA guidelines detect more people with diabetes and prediabetes compared to USPSTF guidelines, but the latter require slightly fewer people to be screened for each diabetes case detected. ADA guidelines would screen 19 adults for each case of diabetes detected, whereas USPSTF would screen 16 adults for each case detected. In other words, ADA appears to be more effective, while USPSTF may be more efficient. The relative efficiency of the two alternative strategies will depend on the costs of screening and the net effect of screening on medical care costs. Screening costs and forecasts of medical cost savings from alternative screening strategies are beyond the scope of the current paper. It is important to note, however, that the detection rates of the two screening options considered here are not very different when considering both diabetes and prediabetes. ADA guidelines result in 2.2 people screened per case detected while USPSTF guidelines result in 2.1 people screened per case detected. Because ADA guidelines screen more people, ADA guidelines identified 38.9% more undetected cases of prediabetes and 24.3% more undetected cases of type 2 diabetes than did the USPSTF guidelines.
ADA guidelines detect more people with diabetes and prediabetes among racial and ethnic minorities and low-income households that historically have had less access to the health care system.
The population detected under ADA guidelines is younger than the population detected under USPSTF guidelines. The health, economic, and quality of life implications of early detection and intervention among younger populations could be quite different from detection among older populations. The lifetime direct medical costs of diabetes for men and women diagnosed between the ages of 25–44 are more than twice the lifetime cost of people diagnosed after age 65—reflecting the fact that people who develop diabetes at earlier ages have more time to develop complications and incur diabetes-related costs . Such findings suggest the potential for substantial lifetime economic benefits to detection and treatment of diabetes at younger ages.
On the question of health care use patterns, our overall findings have two key implications. Our study identified two unique target populations for diagnostic testing: (1) a population in poor health with many contacts with the health care system but no apparent diagnostic testing for prediabetes or type 2 diabetes; and (2) a population who, regardless of health status, had no apparent contact with the health care system and therefore no opportunity for diagnostic testing.
The first population represents a missed opportunity, especially given the number of primary care visits reported by these patients. We will leave to others whether this problem is best addressed through increased patient or provider education, changes in preventive screenings, or other combination of strategies. What is clear is that the missed opportunity is substantial.
The second population, those without contact with the health care system, will require a more innovative approach. Strategies would need to be tested and further research conducted to better identify these people. For example, is their lack of contact due to a lack of health insurance coverage, low income, or cultural reasons? A more refined identification of these people will allow more effective strategies to be developed. One thing is clear: the traditional office-based approach will not work for people who seldom visit a doctor’s office.
Study limitations and areas for future research
This study takes advantage of large, nationally representative data sources to simulate the likely screening and detection implications of ADA and USPSTF screening criteria. The regression models that quantify the relationship between patient characteristics and probability of undiagnosed diabetes and prediabetes show strong goodness of fit, and validation activities suggest the models are robust.
One limitation of this study is the omission of some diabetes risk factors (such as a history of gestational diabetes or family history of diabetes) due to a lack of data in the MEPS. Diagnosed prediabetes is excluded as an explanatory variable from our predictive model because diagnosed prediabetes status is unavailable in the MEPS.
Another limitation is that NHANES does not have follow-up testing, so we were unable to model the risk of false positives or false negatives from screening . The estimated prediction equations, though, are designed to identify population subsets that are at high risk for undetected prediabetes or undiagnosed diabetes (rather than identify individual people who should be screened).
This study uses multiple diagnostic tests in NHANES (HbA1c, FPG, and OGTT) to identify people with undetected diabetes and prediabetes for use in the logistic regression analysis. Almost 100% of the sample received an HbA1c test, half (48%) received an FPG test, and 31% received an OGTT test. The CDC (2011 Diabetes Fact Sheet) uses either FPG or HbA1c in the prediabetes or diabetes range to estimate national prevalence of prediabetes and undiagnosed diabetes—stating that HbA1c and FPG are used because these tests are most often used in clinical practice . CDC notes that use of all three tests, a subset of tests, or individual tests produces different estimates of total prevalence of diabetes and prediabetes.
We conducted sensitivity analyses on the predictive model goodness of fit and use of different diagnostic tests to define prediabetes and undetected diabetes for the regression analysis. We find that use of all three diagnostic tests to define diabetes or prediabetes status produced slightly higher regression intercept estimates than using HbA1c and FPG, but produced similar estimates of odds ratios and prediction outcomes. (We scaled each individual’s predicted probabilities of undiagnosed diabetes and prediabetes by 0.975 so that national totals matched CDC’s national estimates for 2010 of 79 million with prediabetes and 7 million with undiagnosed diabetes.) Using only HbA1c to define diabetes or prediabetes status produced lower regression intercept estimates and a stronger age and racial/ethnic minority effect on probability of prediabetes or undetected diabetes. In terms of overall study findings, using prediction equations based only on HbA1c identified an older population with prediabetes and undiagnosed diabetes than reported in this paper. CDC notes that “Research is ongoing to ascertain the best use of laboratory blood tests to detect people who may have prediabetes and to improve the understanding of who has prediabetes” .
While this analysis focused on the potential to detect diabetes and prediabetes cases in 2010, the full implications of implementing ADA guidelines would take more than one year to manifest, as ADA guidelines call for asymptomatic adults age 45 without risk factors to be screened every three years.
Future research might explore the health, economic, and quality of life implications of detecting diabetes among different subsets of the population (such as younger versus older adults) to better understand the implications of alternative screening guidelines that differ in their ability to detect diabetes and prediabetes among select populations.
Because patients with risk factors for diabetes (such as obesity and hypertension) tend to have greater medical needs, a disproportionate number of patients seeking care in some settings, such as hospital emergency departments, are likely to be at high risk for undiagnosed diabetes or prediabetes. Work by Silverman et al., for example, suggests the prevalence of undiagnosed diabetes and undetected prediabetes among patients admitted to emergency departments for acute illness is 10.5% and 31.9%, respectively . Still, a large study of 2,260 individuals diagnosed with type 2 diabetes found that 88.3% were diagnosed by a family doctor/general practitioner, 4.4% by an endocrinologist, 0.5% by a cardiologist, 0.7% by a neurologist, and 6% by another specialist . This finding highlights the importance of primary care providers in diagnosis of diabetes.
Future research might explore in more depth the health care use patterns of people at high risk for undiagnosed diabetes and why, despite the high volume of care being provided, there are still many people whose diabetes and prediabetes remains undiagnosed.
While this study shows that USPSTF guidelines are slightly more efficient in identifying people with diabetes (in terms of number of people screened to detect each case of diabetes), ADA guidelines are more effective in terms of identifying more people. Ongoing research to investigate the cost-effectiveness of ADA versus USPSTF screening guidelines, in terms of the cost to screen and the cost of intervention among the prediabetic population to prevent or delay diabetes onset and sequelae, would be an essential component for policy decisions in this area.
Early detection is the first step to provide counseling and well-organized, evidence-based intervention to prevent or delay the onset of diabetes among those with prediabetes, and to prevent or delay the onset of complications among people with diabetes. Relative to USPSTF guidelines, ADA guidelines identify more people with prediabetes and undiagnosed diabetes (especially more minority cases) and a younger population that allows for the potential for more effective improvements in quality of life and potentially improved outcomes. The health care use patterns of people at high risk for undiagnosed diabetes and prediabetes combined with the high prevalence of undiagnosed cases suggest that many opportunities for diagnosis are being missed. Many high-risk adults do not receive regular care from a primary care provider, which can hamper detection efforts. As health care system technology, health care use patterns, and medical practice continue to evolve, more effective and efficient methods and criteria for diabetes screening in asymptomatic adults should be sought.
American Diabetes Association
Fasting plasma glucose test
Hemoglobin A1c test
Medical Expenditure Panel Survey
National Health and Nutrition Examination Survey
Oral glucose tolerance test
United States Preventive Services Task Force.
American Diabetes Association: Economic costs of diabetes in the US in 2012. Diabetes Care 2013, 36: 1033-1046.
Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM: The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008, 4: 382-393. 10.1038/ncpendmet0843
Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM: 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 2009, 374: 1677-1686.
American Diabetes Association: Standards of medical care in diabetes--2014. Diabetes Care 2013,37(1):S14-S80. http://care.diabetesjournals.org/content/37/Supplement_1/S14.full.pdf+html
Centers for Disease Control and Prevention: National Diabetes Fact Sheet 2011. US Department of Health and Human Services; 2012. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf
Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S: Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007, 335: 486. 10.1136/bmj.39303.723449.55
Paddison CA, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, Kinmonth AL, Griffin SJ: Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2009, 339: b4535. 10.1136/bmj.b4535
US Preventive Services Task Force: Screening for type 2 diabetes mellitus in adults: recommendation statement. USPSTF 2008. http://www.uspreventiveservicestaskforce.org/uspstf08/type2/type2art.pdf
Collins GS, Mallett S, Omar O, Yu LM: Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med 2011, 9: 103. 10.1186/1741-7015-9-103
Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, Srinivasan BT, Davies MJ: The Leicester Risk Assessment score for detecting undiagnosed type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med 2010, 27: 887-895. 10.1111/j.1464-5491.2010.03037.x
Martin E, Ruf E, Landgraf R, Hauner H, Weinauer F, Martin S: FINDRISK questionnaire combined with HbA1c testing as a potential screening strategy for undiagnosed diabetes in a healthy population. Horm Metab Res 2011, 43: 782-787.
Casagrande SS, Cowie CC, Fradkin JE: Utility of the US Preventive Services Task Force criteria for diabetes screening. Am J Prev Med 2013, 45: 167-174. 10.1016/j.amepre.2013.02.026
Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R, Endocrine Society: Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 2008, 93: 3671-3689. 10.1210/jc.2008-0222
Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovič L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL, AACE Task Force for Developing a Diabetes Comprehensive Care Plan: American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011,17(Suppl 2):1-53.
Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK: 2010 ACCF/AHA Guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary. J Am Coll Cardiol 2010, 56: 2182-2199. 10.1016/j.jacc.2010.09.002
Department of Veterans Affairs, Department of Defense: VA/DoD Clinical practice guideline for the management of diabetes mellitus. 2010.http://www.healthquality.va.gov/guidelines/CD/diabetes/DM2010_FUL-v4e.pdf
Sheehy AM, Flood GE, Tuan WJ, Liou JI, Coursin DB, Smith MA: Analysis of guidelines for screening diabetes mellitus in an ambulatory population. Mayo Clin Proc 2010, 85: 27-35. 10.4065/mcp.2009.0289
Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ: Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010, 375: 1365-1374. 10.1016/S0140-6736(09)62162-0
Centers for Disease Control and Prevention: National Health and Nutrition Examination Survey Data. US Department of Health and Human Services. 2010. http://www.cdc.gov/nchs/nhanes/about_nhanes.htm
Agency for Healthcare Research and Quality (AHRQ): 2010 Medical Expenditure Panel Survey. US Department of Health and Human Services. 2012. http://meps.ahrq.gov/mepsweb/
Christophi CA, Resnick HE, Ratner RE, Temprosa M, Fowler S, Knowler WC, Shamoon H, Barrett-Connor E, Kahn SE: Confirming glycemic status in the diabetes prevention program: implications for diagnosing diabetes in high risk adults. J Diabetes Complications 2013, 27: 150-157. 10.1016/j.jdiacomp.2012.09.012
Zhang Y, Dall TM, Mann SE, Chen Y, Martin J, Moore V, Teutsch SM, Mushlin AI, Kern LM: The economic costs of undiagnosed diabetes. Popul Health Manag 2009, 12: 95-101. 10.1089/pop.2009.12202
Bang H, Edwards AM, Bomback AS, Ballantyne CM, Brillon D, Callahan MA, Teutsch SM, Mushlin AI, Kern LM: Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med 2009, 151: 775-783. 10.7326/0003-4819-151-11-200912010-00005
Robinson CA, Agarwal G, Nerenberg K: Validating the CANRISK prognostic model for assessing diabetes risk in Canada’s multi-ethnic population. Chronic Dis Inj Can 2011, 32: 19-31.
Heikes KE, Eddy DM, Arondekar B, Schlessinger L: Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care 2008, 31: 1040-1045. 10.2337/dc07-1150
van den Donk M, Sandbaek A, Borch-Johnsen K, Lauritzen T, Simmons RK, Wareham NJ, Griffin SJ, Davies MJ, Khunti K, Rutten GEHM: Screening for type 2 diabetes. Lessons from the ADDITION-Europe study. Diabet Med 2011, 28: 1416-1424. 10.1111/j.1464-5491.2011.03365.x
Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ: Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012, 380: 1741-1748. 10.1016/S0140-6736(12)61422-6
The National Heart Lung and Blood Institute, NIDDK: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Institutes of Health; 1998. http://www.nhlbi.nih.gov/guidelines/obesity/index.htm
Biesheuvel CJ, Vergouwe Y, Steyerberg EW, Grobbee DE, Moons KG: Polytomous logistic regression analysis could be applied more often in diagnostic research. J Clin Epidemiol 2008, 61: 125-134. 10.1016/j.jclinepi.2007.03.002
Zhuo X, Zhang P, Hoerger TJ: Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 2013, 45: 253-261. 10.1016/j.amepre.2013.04.017
Zhang P, Engelgau MM, Valdez R, Cadwell B, Benjamin SM, Narayan KM: Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis. Diabetes Care 2005, 28: 1321-1325. 10.2337/diacare.28.6.1321
Silverman RA, Thakker U, Ellman T, Wong I, Smith K, Ito K, Graff K: Hemoglobin A1c as a screen for previously undiagnosed prediabetes and diabetes in an acute-care setting. Diabetes Care 2011, 34: 1908-1912. 10.2337/dc10-0996
Rodbard HW, Green AJ, Fox KM, Grandy S: Trends in method of diagnosis of type 2 diabetes mellitus: results from SHIELD. Int J Endocrinol 2009, 2009: 796206. http://www.hindawi.com/journals/ije/2009/796206/
Funding for this study was provided by Novo Nordisk Inc. Appreciation is expressed to Jerry Franz, Laura Lawlor, and Neil Wintfeld, who commented on earlier versions of this paper, and to Ted Agres, who provided editorial support.
KG is employed by Novo Nordisk Inc. The authors have no other competing interests.
TD is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. TD wrote the manuscript. KMVN, KG, WQ, MO and TB contributed to the discussion and reviewed/edited the manuscript. PG, TB, and MS researched data and contributed to the discussion. TD, KMVN, MS, and PG conceptualized or conducted the statistical analyses. All authors read and approved the final manuscript.